Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive Micrometastatic Disease: The Next Frontier of Research

Documenti analoghi

• Progress in RNA‐Targeted Therapeutics for Human Diseases
  di: Wangzheqi Zhang, et al.
  Pubblicazione: (2026)
• Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies
  di: Liping Liu, et al.
  Pubblicazione: (2025)
• Chimeric Antigen Receptor‐Macrophage Therapy Enters the Clinic: The First‐in‐Human Trial for HER2 + Solid Tumors
  di: Wenxue Ma, et al.
  Pubblicazione: (2025)
• Melanoma: Pathogenesis and Targeted Therapy
  di: Yang Fu, et al.
  Pubblicazione: (2026)
• Phase I Clinical Trial of CVL218, a Novel PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors
  di: Zihong Chen, et al.
  Pubblicazione: (2025)